Dedifferentiated endometrioid adenocarcinoma (DEAC) of the uterus is microscopically characterized by the presence of high-grade areas emerging from low grade tumors. In 2014, DAEC was added to the World Health Organization (WHO) pathological classification of tumors of the uterine corpus. This type of tumor represents the coexistence of an undifferentiated carcinoma (UC, a proliferation of medium size monotonous epithelial cells with no glandular differentiation growing in a patternless solid fashion) and low grade endometrioid adenocarcinoma (most commonly FIGO grade 1 or 2). Presentation of Case: The patient aged 67, with gravida 5 and parity 4, applied to our gynecologic oncology clinic with a diagnosis of endometrial carcinoma. The patient underwent type I abdominal hysterectomy, bilateral salphingo-oophorectomy, bilateral pelvic and para-aortic lymphadenectomy and omental biopsy. The final pathology report confirmed the diagnosis of DEAC with FIGO stage IIIC2. The patient refused to receive adjuvant chemotherapy. Five months after initial surgery, a medical oncology consultation because of a recurrent pelvic mass was offered but the patient refused to get any further treatment options. One month later, the patient died because of disease. Conclusion: Even with a percentage of 20% solid (UC) component, this tumor tends to behave in an aggressive manner. Prognosis is extremely poor therefore exact diagnosis and proper treatment with adjuvant therapy options are essential.
Anahtar Kelimeler: Endometrial carcinoma, Dedifferentiated adenocarcinoma, Chemotherapy
|
